摘要:
The present invention relates to selected (R)-arylalkylamino derivatives of formula (I), in which R, R1 and Ar are as defined in the claims. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.
摘要:
(R)-2-[4-(Trifluoromethanesulphonyloxy)phenyl]propionamide derivatives of_ formula (I), where the variables are as defined in the claims, and pharmaceutical compositions containing such compounds are useful in inhibiting. the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of interieukin-8 (IL-8) with CXCRI and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclooxygenase inhibition. activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
摘要:
A process for the sterilization of water insoluble solid medicinal substances is described.The process provides the sterilization of beclomethasone, which is suitable for pulmonary administration. In particular, the process is used in industrial plants for the production of formulations of sterile beclomethasone for inhalation delivery, so as to avoid any modifications in particle size distribution and in the impurities profile of the drug. The process is carried out by heating a mixture of micronized beclomethasone and purified water only, preferably at a temperature of about 120° C for 20 minutes. The process is particularly efficient and economic for the steam sterilization of beclomethasone dipropionate in formulations for pulmonary delivery.
摘要:
An apparatus is described for micron and submicron particles formation of a substance using the GAS process, comprising a particles formation vessel (22) and means for introducing a solution of the substance and a supercritical fluid into the particles formation vessel (22), wherein said means comprise a nozzle (27) having a central orifice (39) serving to carry a flow of solution, and a plurality of separate outer orifices (41) serving to carry a flow of pure supercritical fluid or a flow of supercritical fluid mixed with a modifier, such that the solvent is extracted from the solution by the supercritical fluid and precipitation of micron and submicron particles occurs. Also a process is described, carried out with such an apparatus.
摘要:
An apparatus is described for micron and submicron particles formation of a substance using the GAS process, comprising a particles formation vessel (22) and means for introducing a solution of the substance and a supercritical fluid into the particles formation vessel (22), wherein said means comprise a nozzle (27) having a central orifice (39) serving to carry a flow of solution, and a plurality of separate outer orifices (41) serving to carry a flow of pure supercritical fluid or a flow of supercritical fluid mixed with a modifier, such that the solvent is extracted from the solution by the supercritical fluid and precipitation of micron and submicron particles occurs. Also a process is described, carried out with such an apparatus.
摘要:
The present information discloses molecular weight markers for Western blot, comprising standard molecular weight markers for SDS-PAGE conjugated with an enzyme having peroxidase activity, e.g. cytochrome C or horseradish peroxidase.
摘要:
A one-step stereoselective process for the preparation of endo-3-aminoazabicycloalkanes from azabicycloalkanones by means of reductive amination is described.
摘要:
Recombinant proteins deriving from recombination of structural domains deriving from the alpha subunits of HGF and/or MSP growth factors. The recombinant proteins of the present invention have biological activity, and protect cells from death (apoptosis) induced by chemotherapeutic drugs. These molecules can conveniently be used to prevent or to treat the toxic side effects of chemotherapeutic agents used in cancer therapy.
摘要:
A process for the co-precipitation of a substance with a stabiliser therefor, by a gas anti solvent process comprising introducing into a particle formation vessel a supercritical fluid pure or mixed with a modifier; and a solution comprising said substance and said stabiliser dissolved in a solvent; so as said solvent is extracted from the solution by said supercritical fluid and co-precipitation of the substance and stabiliser occurs. The process may be carried out using an apparatus comprising a particle formation vessel (22) and a nozzle (27) having a central orifice (39) serving to introduce a solution of the substance and a plurality of outer orifices (41) serving to carry a flow of supercritical fluid into the particle formation vessel (22), such that the solvent is extracted from the solution by the supercritical fluid and precipitation of micron sized particles of the substance/stabilizer occurs. The substance is preferably a protein of pharmaceutical interest, which is highly stabilized for storage by this process.
摘要:
The present invention concerns a GEF mutant in which tryptophan (W) corresponding to position 1056 of the protein called CDC25 is mutated to an acidic amino acid, preferably glutammic acid, or tryptophan (W) at position 1056 and serine at position 1124 are mutated into an acidic acid and valine, respectively. The invention further provides the gene sequences encoding said amino acid sequences, and their application in the treatment of proliferative disorders and in the development of assays suitable for the identification of candidate agents able to disrupt the ras/GEF complex.